



Resource impact statement

Resource impact

Published: 1 February 2023

www.nice.org.uk

No significant resource impact is anticipated

NICE has recommended somatrogen within its marketing authorisation, as an option for treating growth disturbance caused by growth hormone deficiency in children and young people aged 3 years and over.

If people with the condition and their clinicians consider somatrogen to be 1 of a range of suitable treatments (including any preparation of somatropin) discuss the advantages and disadvantages of the available treatments. After that discussion, if more than 1 treatment is suitable, choose the least expensive. Take account of administration costs, dosage, price per dose and commercial arrangements.

We do not expect this guidance to have a significant impact on resources; that is, the resource impact of implementing the recommendations in England will be less than £5 million per year (or approximately £9,000 per 100,000 population, based on a population for England of 56.3 million people).

This is because the technology is a further treatment option and the overall cost of treatment for this patient group will be similar.

This technology is commissioned by integrated care boards. Providers are NHS hospital trusts and primary care providers.